TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07746518: A Multi-center, Double-blind, Randomized, Active-controlled, Parallel-group, Phase III Clinical Trial and Open-label Extension Study to Evaluate the Efficacy and Safety of DWP14012 for Maintenance Therapy in Patients With Healed Erosive Esophagitis

Sponsor: Daewoong Pharmaceutical Co. LTD. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 420 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$15,086,080

Rescue Site Savings

+$9,947,384

Unlock Full NCT07746518 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07746518 Rescue Dossier →